- $93.09m
- $92.54m
- $27.64m
Brief: ImmuCell Announces Preliminary, Unaudited Sales Results For Q3 2023
Brief: Immucell Announces Submission Of Cmc Technical Section To The FDA
Brief: ImmuCell Corporation Q2 product sales USD 3.533 million
Brief: Immucell Corp Anticipates No Change To Preliminary Sales Results For Q2 2023 That Were Disclosed On July 11
Brief: Immucell Announces Change In Timing Of Anticipated FDA Submission
Brief: ImmuCell Appoints Bryan K. Gathagan To Board Of Directors
Brief: Immucell Announces Unaudited Financial Results For The Quarter Ended March 31, 2023
Brief: Immucell Announces Preliminary Unaudited Sales Results For Q1 2023
Brief: Immucell Announces Preliminary Results For The Year Ended Dec. 31, 2022
Brief: ImmuCell Announces Unaudited Financial Results For The Quarter Ended Sept 30, 2022
Brief: Immucell Corp Says Anticipates No Change To Preliminary Sales Results For Q3 Of 2022 That Were Disclosed On October 5
Brief: Immucell Announces Preliminary, Unaudited Sales Q3 Results
Brief: Immucell Announces Unaudited Financial Results For The Quarter Ended June 30, 2022
Brief: Immucell Receives Technical Section Incomplete Letter From FDA Pertaining To Re-Tain
Brief: Immucell Announces Preliminary Sales Results For Q2
Brief: ImmuCell Q1 Sales Up 46% To $6.0 Mln
Brief: Immucell Corp - Sales During First Quarter Ended March 31, 2022 Increased By 46% To $6.0 Million Compared To The Same Period Of The Prior Year
Brief: Immucell Announces Record Preliminary, Unaudited Sales Results For The Year Ended December 31, 2021
Brief: Immucell Announces Unaudited Financial Results For The Third Quarter Ended September 30, 2021